Core Insights - Sonnet BioTherapeutics Holdings, Inc. has received a Notice of Allowance from the USPTO for a second patent related to its modified version of Interleukin-18 (IL-18), which enhances its effectiveness by binding to the IL-18 receptor while avoiding the inhibitory IL-18 Binding Protein [1][2] - The allowed patent covers various amino acid substitutions in the IL-18 protein, potentially opening up licensing opportunities independent of Sonnet's FHAB platform [1][2] - The company is developing two novel drug candidates, SON-1411 and SON-1400, which utilize the FHAB platform to enhance the therapeutic efficacy of IL-18 and IL-12 in oncology [1][4] Company Overview - Sonnet is focused on developing targeted biologic drugs using its proprietary Fully Human Albumin Binding (FHAB) technology, which aims to improve the safety and efficacy of immune-modulating biologic drugs [4] - The lead program, SON-1010, is in clinical development for advanced solid tumors and is being evaluated in combination with Roche's atezolizumab [4] - The company is also advancing SON-080 for Chemotherapy-Induced Peripheral Neuropathy and has entered a licensing agreement with Alkem Laboratories for its development in India [5] Product Details - SON-1411 is a bifunctional fusion protein combining IL-18 and IL-12, designed to enhance immune responses against tumors by stimulating IFNγ production [3][4] - The FHAB technology allows for targeted delivery to tumor and lymphatic tissues, potentially improving the therapeutic window for various cancer treatments [4][5] - SON-1400 is a monofunctional fusion protein that also utilizes the FHAB platform to extend the half-life and biological activity of IL-18 [1][2]
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein